Post-Acquisition Clinical Supply Chain Risk: Continuity Before Consolidation

By Nicolas Letourneau, Ph.D., Founder and Principal, Letourneau Consulting

An acquisition can close with sufficient drug product in storage and still leave a clinical trial exposed to a supply interruption. The material exists, but the people who understand its release history may be leaving or moving into new roles. A supplier may be waiting for instructions from a new contracting entity. The acquiring organization may see inventory in its systems without knowing whether that inventory is usable for the next scheduled visit.

These are clinical supply risks, even when manufacturing and transportation are performing as expected. They arise because ownership, knowledge, and operational responsibility can move at different speeds. For leaders responsible for active trials, the immediate challenge is preserving the connections that allow supply decisions to be made and executed.

My starting point is straightforward: stabilize clinical supply before adopting the acquirer’s operating model. Establish visibility and decision rights immediately, then sequence system migrations and other integration changes around demonstrated operational readiness. A completed organizational handoff does not demonstrate that the receiving team can sustain the next supply cycle.

Why Inventory Alone Can Mislead

Clinical supply serves a protocol whose requirements continue while the organization changes. Usability depends on the right presentation, country and site authorizations, labeling, shelf life, and release status. Where administration requires a device or ancillary supplies, those dependencies belong in the same assessment. Aggregate inventory can offer false reassurance when it is detached from the requirements of a particular trial.

For EU trials, European Medicines Agency guidance describes a two-step investigational medicinal product release process: Qualified Person certification followed by sponsor regulatory release. The product should remain under sponsor control until that process is complete.^[1] A warehouse balance alone cannot establish readiness to supply a site.

ICH Q10 addresses changes in product ownership, including acquisitions. Management should define each company’s continuing responsibilities and ensure essential information transfers.^[2] The operational implication is that acquiring an asset and assuming its supply capability are separate achievements.

Integration can alter several controls simultaneously, making an inherited quality weakness or forecasting error harder to detect or resolve. Leaders should assess those interactions before changing a functioning supply pathway.

Five Risks To Address During Integration

Five areas deserve particular attention because they determine whether the combined organization can understand supply status and act on it.

Knowledge That Does Not Transfer

A complete document repository can still leave the receiving team unable to explain critical assumptions. The rationale for a protected manufacturing slot, a forecast adjustment, or the timing of replacement material may reside largely with people inaccessible during the transition. Losing that context can turn a previously managed constraint into an unexpected delay.

ICH Q10 treats product and process knowledge as a life cycle responsibility.^[2] Ask the receiving team to explain the supply plan, its assumptions, and its failure conditions. Keep critical experts available until the receiving team can demonstrate that understanding, and capture decision rationale alongside the underlying records. A document transfer should not be the sole acceptance criterion for knowledge transfer.

Decision Rights That Become Ambiguous

An organization chart identifies reporting relationships; it may leave unresolved who can disposition materials involved in a temperature excursion, authorize a shipment, or escalate a release delay. During integration, legacy and acquiring teams may each assume the other owns the next decision. A schedule can slip while the issue waits between functions. This is especially important when the organizations differ substantially in size: one person in a smaller company may hold roles that a larger company distributes across several people. Map the handoff of each responsibility explicitly.

Where service providers perform trial activities, ICH E6(R3) leaves ultimate responsibility for the sponsor’s activities with the sponsor and calls for documented agreements and oversight.^[3] Apply that principle through named decision owners and backups, with clear boundaries between quality disposition, regulatory release, and operational execution. A named continuity lead should coordinate these decisions without assuming authority reserved for qualified or authorized functions. Test whether a time-sensitive exception can reach the appropriate decision maker before it jeopardizes the next shipment.

Data That Lose Their Operational Meaning

Inventory records must retain the meaning of status as they move between systems. In a hypothetical migration, a depot’s physical stock count transfers correctly while its quarantine status does not. The quantity reconciles, yet the receiving system presents material as available that the team cannot release. Accurate totals conceal an operational mismatch.

E6(R3) calls for validated or otherwise appropriate processes to preserve data integrity and confidentiality during transfer and migration, with documented traceability and appropriate reconciliation.^[3] For supply integration, reconcile the fields that drive decisions: lot and kit identity, release status, expiry, location, and allocation. Preserve blinding and access controls. Identify the authoritative record for each field, then test a representative resupply transaction through to execution. Preserve the demand model’s enrollment and dosing assumptions as well; a new system should not silently reset the forecast. A successful data import is only one part of demonstrating that the new process works.

Supplier Continuity That Is Assumed

A supplier relationship has commercial, technical, and quality dimensions. Updating a purchase order does not establish that the supplier has accepted changed responsibilities, that manufacturing capacity remains reserved, or that the receiving organization can access the records needed for release. Each dependency needs an owner and evidence of continuity.

Review assignment and change-of-control provisions with legal and procurement stakeholders, while technical and quality leaders confirm what the supplier must continue delivering. Keep commercial arrangements aligned with the written allocation of sponsor and manufacturer responsibilities described in applicable guidance, such as the EU guidance on investigational medicinal products.^[1] Where a transfer is planned, define the support, information access, and supply coverage needed until the receiving operation meets agreed operational readiness criteria. Track contract completion and operational readiness separately. Confirm with legal and quality leaders whether existing agreements remain valid and cover the new responsibilities; put any required amendments or replacement agreements in place before the affected activities proceed.

Integration Incentives That Outpace Operational Readiness

Consolidating suppliers or retiring a legacy system can look like progress on an integration dashboard while removing a capability that an active trial still needs. The risk increases when projected savings are clear but the assumptions supporting continued supply are untested.

ICH Q9(R1) addresses product availability risks arising from quality and manufacturing issues, including supply-chain interdependencies.^[4] Use that principle to challenge the sequence of proposed changes. Preserve a compliant supply pathway until its replacement is demonstrated, while addressing inherited quality deficiencies promptly. Not every risk surfaces during diligence; some depend on day-to-day practices that may not be fully visible before close. Plan for inherited issues that could threaten supply continuity, and establish a framework for managing them. Stabilization includes remediation when existing controls are inadequate; it is not a reason to defer necessary improvements.

A Leadership Framework For Continuity

Before close, within permitted diligence arrangements, map the next supply cycle for each active trial. Link usable inventory and forecast demand to release dependencies, replenishment lead times, and critical suppliers. Identify who holds the knowledge needed to explain that plan. Surface gaps early enough for transition arrangements to address them.

At close, establish a named continuity lead, functional decision owners, and appropriate escalation routes. Confirm access to essential records and reconcile supply status. Give suppliers, depots, and affected study teams clear instructions about contacts and responsibilities. Regulatory stakeholders should determine whether and how the transaction affects the legal sponsor or triggers other jurisdiction-specific actions. Corporate ownership and legal sponsorship should be assessed separately.

During the first 100 days and subsequent transitions, use evidence of operational readiness to assess and authorize changes. Have the receiving team demonstrate a routine resupply and work through a realistic exception, such as a batch that cannot be released or a temperature excursion. Confirm that the team can retrieve records, make authorized decisions, and instruct depots and sites within the available supply window. Define fallback plans, their owners, and the triggers for using them before retiring the legacy process. Test contingency arrangements proportionately to the risk.

Track measures that reveal exposure: demand covered by usable inventory, time remaining to resolve release constraints, unresolved inventory discrepancies, and dependencies that threaten replenishment. Compare supply coverage with the time needed to recover from a credible failure, allowing for uncertainty in the estimates. These phases are a management framework, not regulatory deadlines. Some transitions can proceed quickly; others need controlled overlap, with explicit ownership and an agreed endpoint.

Clinical Supply Continuity As An Integration Objective

Clinical supply continuity deserves explicit ownership in the acquisition plan because it depends on decisions across the organization. Integration leaders should be able to show how the next supply cycle will work, what could interrupt it, and who can respond while there is still time.

Standardization can improve long-term control, but its timing should follow operational evidence. Evaluate projected savings alongside the potential cost of disrupted studies or delayed study starts. Measure integration progress by the acquiring organization’s ability to sustain supply through the change. For patients and study teams, the meaningful outcome is that a change in corporate ownership does not create an avoidable interruption to an ongoing trial.

References

1. European Medicines Agency. Guideline on the responsibilities of the sponsor with regard to handling and shipping of investigational medicinal products for human use in accordance with Good Clinical Practice and Good Manufacturing Practice. Sept. 14, 2022; effective Jan. 1, 2023. EMA/INS/GMP/258937/2022. Sections 2 and 4.
2. U.S. Food and Drug Administration. Q10 Pharmaceutical Quality System. April 2009. ICH sections 1.6.1 and 2.8.
3. U.S. Food and Drug Administration. E6(R3) Good Clinical Practice. September 2025. Annex 1, ICH sections 3.6.4, 3.6.6, 3.6.9, 4.1, 4.2.5, and 4.3.8.
4. U.S. Food and Drug Administration. Q9(R1) Quality Risk Management. May 2023. ICH section 6.1.

About The Author

Nicolas Letourneau, Ph.D., is the founder and principal of Letourneau Consulting, a strategic technical advisory firm serving life science companies. He brings more than 15 years of experience across biopharma, medical devices, diagnostics, and combination products. He advises leadership teams on clinical readiness, technical operations, acquisition diligence, and post-acquisition integration. His work spans device development, chemistry, manufacturing, and controls (CMC), quality, regulatory strategy, and external partner coordination. He helps organizations assess technical risk, clarify responsibilities, and plan transitions around program needs. His approach to integration emphasizes knowledge transfer, documentation ownership, supplier readiness, and continuity of development and clinical supply.